Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1)

被引：0
作者：
Luis Baez-Vallecillo
Akshara S. Raghavendra
Kenneth R. Hess
Carlos H. Barcenas
Stacy L. Moulder
Debu Tripathy
Vicente Valero
Rashmi K. Murthy
机构：
[1] The University of Texas MD Anderson Cancer Center,Division of Cancer Medicine – Hematology/Oncology Fellowship Program
[2] The University of Texas MD Anderson Cancer Center,Biostatistics
[3] The University of Texas MD Anderson Cancer Center,Division of Cancer Medicine, Department of Breast Medical Oncology
来源：
Breast Cancer Research and Treatment | 2019年 / 176卷
关键词：
Lapatinib; Trastuzumab; Pertuzumab; T-DM1; HER2; Breast cancer; Metastatic;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：227 / 234
页数：7
相关论文
共 33 条
  • [1] Yarden Y(1987)Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand EMBO J 6 3341-3351
  • [2] Slamon DJ(1987)Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177-182
  • [3] Slamon DJ(2001)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783-792
  • [4] Slamon D(2011)Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 1273-1283
  • [5] Romond EH(2005)Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673-1684
  • [6] Piccart-Gebhart MJ(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1672
  • [7] Geyer CE(2006)Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733-2743
  • [8] Blackwell KL(2010)Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 28 1124-1130
  • [9] Blackwell KL(2012)Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study J Clin Oncol 30 2585-2592
  • [10] Baselga J(2012)Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 109-119
1234